Maintenance  ||| S:0 E:12 ||| NN
of  ||| S:12 E:15 ||| IN
autoantibody  ||| S:15 E:28 ||| JJ
production  ||| S:28 E:39 ||| NN
in  ||| S:39 E:42 ||| IN
pristane-induced  ||| S:42 E:59 ||| JJ
murine  ||| S:59 E:66 ||| NNS
lupus  ||| S:66 E:72 ||| VBP
Pristane-treated  ||| S:72 E:89 ||| JJ
mice  ||| S:89 E:94 ||| NNS
chronically  ||| S:94 E:106 ||| RB
produce  ||| S:106 E:114 ||| VB
high  ||| S:114 E:119 ||| JJ
levels  ||| S:119 E:126 ||| NNS
of  ||| S:126 E:129 ||| IN
anti-ribonucleoprotein ||| S:129 E:151 ||| NNP
/ ||| S:151 E:152 ||| NNP
Smith  ||| S:152 E:158 ||| NNP
( ||| S:158 E:159 ||| -LRB-
anti-Sm ||| S:159 E:166 ||| NNP
/ ||| S:166 E:167 ||| NNP
RNP ||| S:167 E:170 ||| NNP
)  ||| S:170 E:172 ||| -RRB-
and  ||| S:172 E:176 ||| CC
other  ||| S:176 E:182 ||| JJ
lupus  ||| S:182 E:188 ||| JJ
autoantibodies ||| S:188 E:202 ||| NN
.  ||| S:202 E:204 ||| .
The  ||| S:204 E:208 ||| DT
present  ||| S:208 E:216 ||| JJ
study  ||| S:216 E:222 ||| NN
addressed  ||| S:222 E:232 ||| VBD
how  ||| S:232 E:236 ||| WRB
these  ||| S:236 E:242 ||| DT
autoantibody  ||| S:242 E:255 ||| JJ
levels  ||| S:255 E:262 ||| NNS
are  ||| S:262 E:266 ||| VBP
maintained  ||| S:266 E:277 ||| VBN
over  ||| S:277 E:282 ||| IN
time ||| S:282 E:286 ||| NN
.  ||| S:286 E:288 ||| .
Lupus  ||| S:288 E:294 ||| NNP
was  ||| S:294 E:298 ||| VBD
induced  ||| S:298 E:306 ||| VBN
in  ||| S:306 E:309 ||| IN
BALB ||| S:309 E:313 ||| NNP
/ ||| S:313 E:314 ||| NNP
c  ||| S:314 E:316 ||| SYM
mice  ||| S:316 E:321 ||| FW
using  ||| S:321 E:327 ||| FW
pristane ||| S:327 E:335 ||| FW
.  ||| S:335 E:337 ||| .
Naïve  ||| S:337 E:343 ||| NNP
B  ||| S:343 E:345 ||| NNP
cells ||| S:345 E:350 ||| NNS
,  ||| S:350 E:352 ||| ,
switched  ||| S:352 E:361 ||| VBD
memory  ||| S:361 E:368 ||| NN
B  ||| S:368 E:370 ||| NN
cells ||| S:370 E:375 ||| NNS
,  ||| S:375 E:377 ||| ,
switched  ||| S:377 E:386 ||| VBD
plasmablasts ||| S:386 E:398 ||| CD
,  ||| S:398 E:400 ||| ,
and  ||| S:400 E:404 ||| CC
plasma  ||| S:404 E:411 ||| JJ
cells  ||| S:411 E:417 ||| NNS
were  ||| S:417 E:422 ||| VBD
flow-sorted  ||| S:422 E:434 ||| JJ
and  ||| S:434 E:438 ||| CC
total  ||| S:438 E:444 ||| JJ
IgG  ||| S:444 E:448 ||| JJ
and  ||| S:448 E:452 ||| CC
anti-U1A  ||| S:452 E:461 ||| NNP
( ||| S:461 E:462 ||| -LRB-
RNP ||| S:462 E:465 ||| NNP
)  ||| S:465 E:467 ||| -RRB-
autoantibodies  ||| S:467 E:482 ||| NN
were  ||| S:482 E:487 ||| VBD
determined  ||| S:487 E:498 ||| VBN
with  ||| S:498 E:503 ||| IN
ELISA ||| S:503 E:508 ||| NNP
.  ||| S:508 E:510 ||| .
B  ||| S:510 E:512 ||| NNP
cells  ||| S:512 E:518 ||| NNS
with  ||| S:518 E:523 ||| IN
a  ||| S:523 E:525 ||| DT
switched  ||| S:525 E:534 ||| JJ
memory-like  ||| S:534 E:546 ||| NN
( ||| S:546 E:547 ||| -LRB-
CD19 ||| S:547 E:551 ||| NNP
( ||| S:551 E:552 ||| -LRB-
+ ||| S:552 E:553 ||| NNP
) ||| S:553 E:554 ||| -RRB-
CD138 ||| S:554 E:559 ||| NNP
( ||| S:559 E:560 ||| -LRB-
- ||| S:560 E:561 ||| NNP
) ||| S:561 E:562 ||| -RRB-
IgM ||| S:562 E:565 ||| NNP
( ||| S:565 E:566 ||| -LRB-
- ||| S:566 E:567 ||| NNP
) ||| S:567 E:568 ||| -RRB-
IgD ||| S:568 E:571 ||| NNP
( ||| S:571 E:572 ||| -LRB-
- ||| S:572 E:573 ||| NNP
) ||| S:573 E:574 ||| -RRB-
)  ||| S:574 E:576 ||| -RRB-
( ||| S:576 E:577 ||| -LRB-
sMB ||| S:577 E:580 ||| NNP
)  ||| S:580 E:582 ||| -RRB-
phenotype  ||| S:582 E:592 ||| NN
were  ||| S:592 E:597 ||| VBD
increased  ||| S:597 E:607 ||| VBN
in  ||| S:607 E:610 ||| IN
pristane-treated  ||| S:610 E:627 ||| JJ
mice  ||| S:627 E:632 ||| NNS
and  ||| S:632 E:636 ||| CC
expressed  ||| S:636 E:646 ||| VBD
higher  ||| S:646 E:653 ||| JJR
levels  ||| S:653 E:660 ||| NNS
of  ||| S:660 E:663 ||| IN
Toll  ||| S:663 E:668 ||| NNP
like  ||| S:668 E:673 ||| IN
receptor  ||| S:673 E:682 ||| CD
7  ||| S:682 E:684 ||| CD
( ||| S:684 E:685 ||| -LRB-
Tlr7 ||| S:685 E:689 ||| NNP
)  ||| S:689 E:691 ||| -RRB-
than  ||| S:691 E:696 ||| IN
cells  ||| S:696 E:702 ||| NNS
with  ||| S:702 E:707 ||| IN
this  ||| S:707 E:712 ||| DT
phenotype  ||| S:712 E:722 ||| NN
from  ||| S:722 E:727 ||| IN
untreated  ||| S:727 E:737 ||| JJ
mice ||| S:737 E:741 ||| NNS
.  ||| S:741 E:743 ||| .
Flow-sorted  ||| S:743 E:755 ||| JJ
sMB  ||| S:755 E:759 ||| JJ
cells  ||| S:759 E:765 ||| NNS
from  ||| S:765 E:770 ||| IN
pristane-treated  ||| S:770 E:787 ||| JJ
mice  ||| S:787 E:792 ||| NNS
did  ||| S:792 E:796 ||| VBD
not  ||| S:796 E:800 ||| RB
secrete  ||| S:800 E:808 ||| JJ
IgG  ||| S:808 E:812 ||| JJ
spontaneously ||| S:812 E:825 ||| NN
,  ||| S:825 E:827 ||| ,
but  ||| S:827 E:831 ||| CC
were  ||| S:831 E:836 ||| VBD
hyper-responsive  ||| S:836 E:853 ||| JJ
to  ||| S:853 E:856 ||| TO
both  ||| S:856 E:861 ||| DT
synthetic  ||| S:861 E:871 ||| JJ
( ||| S:871 E:872 ||| -LRB-
R848 ||| S:872 E:876 ||| NNP
)  ||| S:876 E:878 ||| -RRB-
and  ||| S:878 E:882 ||| CC
natural  ||| S:882 E:890 ||| JJ
( ||| S:890 E:891 ||| -LRB-
apoptotic  ||| S:891 E:901 ||| JJ
cells ||| S:901 E:906 ||| NNS
)  ||| S:906 E:908 ||| -RRB-
TLR7  ||| S:908 E:913 ||| CD
ligands ||| S:913 E:920 ||| NN
,  ||| S:920 E:922 ||| ,
resulting  ||| S:922 E:932 ||| VBG
in  ||| S:932 E:935 ||| IN
increased  ||| S:935 E:945 ||| JJ
IgG  ||| S:945 E:949 ||| JJ
production  ||| S:949 E:960 ||| NN
in  ||| S:960 E:963 ||| IN
vitro ||| S:963 E:968 ||| NN
.  ||| S:968 E:970 ||| .
The  ||| S:970 E:974 ||| DT
flow-sorted  ||| S:974 E:986 ||| JJ
sMB  ||| S:986 E:990 ||| JJ
cells  ||| S:990 E:996 ||| NNS
also  ||| S:996 E:1001 ||| RB
could  ||| S:1001 E:1007 ||| MD
be  ||| S:1007 E:1010 ||| VB
driven  ||| S:1010 E:1017 ||| VBN
by  ||| S:1017 E:1020 ||| IN
R848  ||| S:1020 E:1025 ||| CD
to  ||| S:1025 E:1028 ||| TO
produce  ||| S:1028 E:1036 ||| VB
IgG  ||| S:1036 E:1040 ||| JJ
anti-U1A  ||| S:1040 E:1049 ||| CD
autoantibodies ||| S:1049 E:1063 ||| NNS
.  ||| S:1063 E:1065 ||| .
Production  ||| S:1065 E:1076 ||| NN
of  ||| S:1076 E:1079 ||| IN
IgG  ||| S:1079 E:1083 ||| NNP
was  ||| S:1083 E:1087 ||| VBD
strongly  ||| S:1087 E:1096 ||| RB
inhibited  ||| S:1096 E:1106 ||| VBN
by  ||| S:1106 E:1109 ||| IN
both  ||| S:1109 E:1114 ||| DT
JSH-23  ||| S:1114 E:1121 ||| NNP
and  ||| S:1121 E:1125 ||| CC
SB203580 ||| S:1125 E:1133 ||| NNP
,  ||| S:1133 E:1135 ||| ,
suggesting  ||| S:1135 E:1146 ||| VBG
that  ||| S:1146 E:1151 ||| IN
the  ||| S:1151 E:1155 ||| DT
canonical  ||| S:1155 E:1165 ||| JJ
NFκB  ||| S:1165 E:1170 ||| JJ
and  ||| S:1170 E:1174 ||| CC
p38  ||| S:1174 E:1178 ||| NNP
MAPK  ||| S:1178 E:1183 ||| NNP
pathways ||| S:1183 E:1191 ||| NN
,  ||| S:1191 E:1193 ||| ,
respectively ||| S:1193 E:1205 ||| RB
,  ||| S:1205 E:1207 ||| ,
contribute  ||| S:1207 E:1218 ||| VBP
to  ||| S:1218 E:1221 ||| TO
the  ||| S:1221 E:1225 ||| DT
TLR7  ||| S:1225 E:1230 ||| JJ
ligand  ||| S:1230 E:1237 ||| JJ
hyper-responsiveness  ||| S:1237 E:1258 ||| NN
of  ||| S:1258 E:1261 ||| IN
sMB  ||| S:1261 E:1265 ||| JJ
from  ||| S:1265 E:1270 ||| IN
pristane-treated  ||| S:1270 E:1287 ||| JJ
mice ||| S:1287 E:1291 ||| NNS
.  ||| S:1291 E:1293 ||| .
The  ||| S:1293 E:1297 ||| DT
switched  ||| S:1297 E:1306 ||| JJ
memory  ||| S:1306 E:1313 ||| NN
B  ||| S:1313 E:1315 ||| NN
cell  ||| S:1315 E:1320 ||| NN
subset  ||| S:1320 E:1327 ||| NN
from  ||| S:1327 E:1332 ||| IN
pristane-treated  ||| S:1332 E:1349 ||| JJ
mice  ||| S:1349 E:1354 ||| NNS
is  ||| S:1354 E:1357 ||| VBZ
expanded  ||| S:1357 E:1366 ||| VBN
and  ||| S:1366 E:1370 ||| CC
shows  ||| S:1370 E:1376 ||| VBZ
an  ||| S:1376 E:1379 ||| DT
increased  ||| S:1379 E:1389 ||| JJ
propensity  ||| S:1389 E:1400 ||| NN
to  ||| S:1400 E:1403 ||| TO
undergo  ||| S:1403 E:1411 ||| VB
terminal  ||| S:1411 E:1420 ||| NN
( ||| S:1420 E:1421 ||| -LRB-
plasma  ||| S:1421 E:1428 ||| JJ
cell ||| S:1428 E:1432 ||| NN
)  ||| S:1432 E:1434 ||| -RRB-
differentiation  ||| S:1434 E:1450 ||| NN
in  ||| S:1450 E:1453 ||| IN
response  ||| S:1453 E:1462 ||| NN
to  ||| S:1462 E:1465 ||| TO
synthetic  ||| S:1465 E:1475 ||| JJ
and  ||| S:1475 E:1479 ||| CC
natural  ||| S:1479 E:1487 ||| JJ
TLR7  ||| S:1487 E:1492 ||| CD
ligands ||| S:1492 E:1499 ||| NNS
.  ||| S:1499 E:1501 ||| .
The  ||| S:1501 E:1505 ||| DT
data  ||| S:1505 E:1510 ||| NNS
suggest  ||| S:1510 E:1518 ||| VBP
that  ||| S:1518 E:1523 ||| IN
the  ||| S:1523 E:1527 ||| DT
decreased  ||| S:1527 E:1537 ||| JJ
clearance  ||| S:1537 E:1547 ||| NN
of  ||| S:1547 E:1550 ||| IN
apoptotic  ||| S:1550 E:1560 ||| JJ
cells  ||| S:1560 E:1566 ||| NNS
characteristic  ||| S:1566 E:1581 ||| NN
of  ||| S:1581 E:1584 ||| IN
pristane-treated  ||| S:1584 E:1601 ||| JJ
mice  ||| S:1601 E:1606 ||| NNS
might  ||| S:1606 E:1612 ||| MD
help  ||| S:1612 E:1617 ||| VB
maintain  ||| S:1617 E:1626 ||| VB
high  ||| S:1626 E:1631 ||| JJ
serum  ||| S:1631 E:1637 ||| JJ
levels  ||| S:1637 E:1644 ||| NNS
of  ||| S:1644 E:1647 ||| IN
anti-RNP ||| S:1647 E:1655 ||| NNP
/ ||| S:1655 E:1656 ||| NNP
Sm  ||| S:1656 E:1659 ||| NNP
autoantibodies ||| S:1659 E:1673 ||| NN
.  ||| S:1673 E:1675 ||| .
